Cargando…

Hepatitis E Virus Infection, a Risk for Liver Transplant Recipients in Sweden

Following exposure to hepatitis E virus (HEV), liver transplant (LT) recipients have an increased risk of developing chronic infection, which may rapidly progress to severe liver damage if not treated. The prevalence of HEV infection after LT is unclear and likely varies geographically. The aim of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Frankal, Miriam, Skoglund, Catarina, Castedal, Maria, Lagging, Martin, Norder, Heléne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666183/
https://www.ncbi.nlm.nih.gov/pubmed/36398195
http://dx.doi.org/10.1097/TXD.0000000000001409
_version_ 1784831446803808256
author Frankal, Miriam
Skoglund, Catarina
Castedal, Maria
Lagging, Martin
Norder, Heléne
author_facet Frankal, Miriam
Skoglund, Catarina
Castedal, Maria
Lagging, Martin
Norder, Heléne
author_sort Frankal, Miriam
collection PubMed
description Following exposure to hepatitis E virus (HEV), liver transplant (LT) recipients have an increased risk of developing chronic infection, which may rapidly progress to severe liver damage if not treated. The prevalence of HEV infection after LT is unclear and likely varies geographically. The aim of this study was to investigate the prevalence of acute and chronic HEV infection among LT recipients in an HEV endemic region. METHODS. During 2013 to 2015, 109 of 152 prospectively enrolled patients listed for LT received a liver graft and completed the study protocol. They were evaluated for anti-HEV IgM, HEV IgG, and HEV RNA at the time of LT assessment and 3 and 12 mo post-LT. Medical records were reviewed. RESULTS. Twelve (11%) LT recipients acquired markers of HEV infection during the study period. Seven patients (6%) had detectable HEV RNA, 1 before LT and 3 at the 3-mo and another 3 at the 12-mo follow-up post-LT. All resolved their infections without treatment and had undetectable HEV RNA at the succeeding follow-up. Another 5 (5%) patients developed anti-HEV antibodies without detectable HEV RNA as an indication of HEV infection during follow-up. Signs and symptoms of HEV infection were subtle‚ and none were diagnosed in routine clinical care. CONCLUSION. A substantial proportion of LT recipients in Sweden are at risk of acquiring HEV infection, both before and after LT. The results highlight the frequency of silent, spontaneously resolving HEV infections and do not support universal screening of LT recipients in Sweden, despite HEV being a potentially treatable infection.
format Online
Article
Text
id pubmed-9666183
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-96661832022-11-16 Hepatitis E Virus Infection, a Risk for Liver Transplant Recipients in Sweden Frankal, Miriam Skoglund, Catarina Castedal, Maria Lagging, Martin Norder, Heléne Transplant Direct Infectious Disease Following exposure to hepatitis E virus (HEV), liver transplant (LT) recipients have an increased risk of developing chronic infection, which may rapidly progress to severe liver damage if not treated. The prevalence of HEV infection after LT is unclear and likely varies geographically. The aim of this study was to investigate the prevalence of acute and chronic HEV infection among LT recipients in an HEV endemic region. METHODS. During 2013 to 2015, 109 of 152 prospectively enrolled patients listed for LT received a liver graft and completed the study protocol. They were evaluated for anti-HEV IgM, HEV IgG, and HEV RNA at the time of LT assessment and 3 and 12 mo post-LT. Medical records were reviewed. RESULTS. Twelve (11%) LT recipients acquired markers of HEV infection during the study period. Seven patients (6%) had detectable HEV RNA, 1 before LT and 3 at the 3-mo and another 3 at the 12-mo follow-up post-LT. All resolved their infections without treatment and had undetectable HEV RNA at the succeeding follow-up. Another 5 (5%) patients developed anti-HEV antibodies without detectable HEV RNA as an indication of HEV infection during follow-up. Signs and symptoms of HEV infection were subtle‚ and none were diagnosed in routine clinical care. CONCLUSION. A substantial proportion of LT recipients in Sweden are at risk of acquiring HEV infection, both before and after LT. The results highlight the frequency of silent, spontaneously resolving HEV infections and do not support universal screening of LT recipients in Sweden, despite HEV being a potentially treatable infection. Lippincott Williams & Wilkins 2022-11-11 /pmc/articles/PMC9666183/ /pubmed/36398195 http://dx.doi.org/10.1097/TXD.0000000000001409 Text en Copyright © 2022 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Infectious Disease
Frankal, Miriam
Skoglund, Catarina
Castedal, Maria
Lagging, Martin
Norder, Heléne
Hepatitis E Virus Infection, a Risk for Liver Transplant Recipients in Sweden
title Hepatitis E Virus Infection, a Risk for Liver Transplant Recipients in Sweden
title_full Hepatitis E Virus Infection, a Risk for Liver Transplant Recipients in Sweden
title_fullStr Hepatitis E Virus Infection, a Risk for Liver Transplant Recipients in Sweden
title_full_unstemmed Hepatitis E Virus Infection, a Risk for Liver Transplant Recipients in Sweden
title_short Hepatitis E Virus Infection, a Risk for Liver Transplant Recipients in Sweden
title_sort hepatitis e virus infection, a risk for liver transplant recipients in sweden
topic Infectious Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666183/
https://www.ncbi.nlm.nih.gov/pubmed/36398195
http://dx.doi.org/10.1097/TXD.0000000000001409
work_keys_str_mv AT frankalmiriam hepatitisevirusinfectionariskforlivertransplantrecipientsinsweden
AT skoglundcatarina hepatitisevirusinfectionariskforlivertransplantrecipientsinsweden
AT castedalmaria hepatitisevirusinfectionariskforlivertransplantrecipientsinsweden
AT laggingmartin hepatitisevirusinfectionariskforlivertransplantrecipientsinsweden
AT norderhelene hepatitisevirusinfectionariskforlivertransplantrecipientsinsweden